Protagonist Therapeutics, Inc (PTGX) stock
PTGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 12/30199% above fair value
$127.16+2.49 (+2.00%)
Close on Nov 18, 2026Market cap $8.23BP/E 123.5Yield –
Protagonist Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Protagonist Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $281.99M, up 34.8% year over year. For fiscal 2025 it was $46.02M, down 89.4% from the year before. The highest annual figure on record is $434.43M in fiscal 2024.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $46.02M | -89.4% |
| FY2024 | Dec 31, 2024 | $434.43M | +624.1% |
| FY2023 | Dec 31, 2023 | $60.00M | +125.7% |
| FY2022 | Dec 31, 2022 | $26.58M | -2.8% |
| FY2021 | Dec 31, 2021 | $27.36M | -4.4% |
| FY2020 | Dec 31, 2020 | $28.63M | +12293.1% |
| FY2019 | Dec 31, 2019 | $231.00K | -99.3% |
| FY2018 | Dec 31, 2018 | $30.93M | +54.1% |
| FY2017 | Dec 31, 2017 | $20.06M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $213.48M | +3749.2% |
| Q1 FY2026 | Mar 31, 2026 | $56.37M | +99.0% |
| Q4 FY2025 | Dec 31, 2025 | $7.44M | -95.6% |
| Q3 FY2025 | Sep 30, 2025 | $4.71M | +0.8% |
| Q2 FY2025 | Jun 30, 2025 | $5.55M | +33.1% |
| Q1 FY2025 | Mar 31, 2025 | $28.32M | -88.9% |
| Q4 FY2024 | Dec 31, 2024 | $170.64M | +184.4% |
| Q3 FY2024 | Sep 30, 2024 | $4.68M | – |
| Q2 FY2024 | Jun 30, 2024 | $4.17M | – |
| Q1 FY2024 | Mar 31, 2024 | $254.95M | – |
| Q4 FY2023 | Dec 31, 2023 | $60.00M | – |
| Q3 FY2023 | Sep 30, 2023 | $0 | – |
| Q2 FY2023 | Jun 30, 2023 | $0 | -100.0% |
| Q1 FY2023 | Mar 31, 2023 | $0 | -100.0% |
| Q4 FY2022 | Dec 31, 2022 | $0 | -100.0% |
| Q3 FY2022 | Sep 30, 2022 | $0 | -100.0% |
| Q2 FY2022 | Jun 30, 2022 | $859.00K | -62.1% |
| Q1 FY2022 | Mar 31, 2022 | $25.72M | +315.6% |
| Q4 FY2021 | Dec 31, 2021 | $8.62M | +52.5% |
| Q3 FY2021 | Sep 30, 2021 | $10.29M | -21.6% |
| Q2 FY2021 | Jun 30, 2021 | $2.27M | -16.7% |
| Q1 FY2021 | Mar 31, 2021 | $6.19M | +49.5% |
| Q4 FY2020 | Dec 31, 2020 | $5.65M | +262.2% |
| Q3 FY2020 | Sep 30, 2020 | $13.11M | +457.3% |
| Q4 FY2019 | Dec 31, 2019 | $2.72M | -55.6% |
| Q3 FY2019 | Sep 30, 2019 | $4.14M | -64.5% |
| Q1 FY2019 | Mar 31, 2019 | $1.56M | -85.5% |
| Q4 FY2018 | Dec 31, 2018 | $2.35M | -79.1% |
| Q3 FY2018 | Sep 30, 2018 | $6.12M | -30.3% |
| Q2 FY2018 | Jun 30, 2018 | $11.67M | – |
| Q1 FY2018 | Mar 31, 2018 | $10.78M | – |
| Q4 FY2017 | Dec 31, 2017 | $11.28M | – |
| Q3 FY2017 | Sep 30, 2017 | $8.78M | – |
| Q3 FY2016 | Sep 30, 2016 | $0 | – |
See a number that looks wrong?